河南科技大学学报(医学版)
河南科技大學學報(醫學版)
하남과기대학학보(의학판)
JOURNAL OF HENAN UNIVERSITY OF SCIENCE & TECHNOLOGY(MEDICAL SCIENCE)
2015年
2期
93-96
,共4页
信必可都保%阿托伐他汀钙%慢性阻塞性肺疾病急性加重期%炎症因子%肺功能
信必可都保%阿託伐他汀鈣%慢性阻塞性肺疾病急性加重期%炎癥因子%肺功能
신필가도보%아탁벌타정개%만성조새성폐질병급성가중기%염증인자%폐공능
Symbicort Turbuhaler%Atorvastatin calcium%acute exacerbation of chronic obstructive pulmonary disease%inflammatory factors%lung function
目的:观察布地奈德福莫特罗吸入剂(信必可都保)联合阿托伐他汀钙对慢性阻塞性肺疾病急性加重期(AECOPD)患者炎症因子及肺功能的影响。方法将100例 AECOPD 患者按入院的先后顺序分为研究组和对照组,每组50例。对照组给予抗生素、多索茶碱、阿托伐他汀钙等常规基础治疗;观察组在对照组常规治疗基础上加用信必可都保吸入。观察治疗前、治疗14 d 后两组患者血清白细胞介素(IL-13)、C 反应蛋白(CRP)表达水平及肺功能的变化。结果治疗前两组患者血清 IL-13、CRP 表达水平及肺功能比较差异无统计学意义(P >0.05)。治疗14 d 后,观察组患者血清 IL-13、CRP 表达水平明显降低(P <0.05),肺活量(FVC)、最大呼气峰流速(PEF)、第1秒用力呼气容积(FEV1)、第1秒用力呼气容积占用力肺活量之比(FEV1/FVC)变化明显高于对照组(P <0.05),观察组总有效率明显高于对照组(P <0.05)。结论信必可都保联合阿托伐他汀钙能明显降低慢性阻塞性肺疾病急性加重期患者炎症因子水平,显著改善肺功能。
目的:觀察佈地奈德福莫特囉吸入劑(信必可都保)聯閤阿託伐他汀鈣對慢性阻塞性肺疾病急性加重期(AECOPD)患者炎癥因子及肺功能的影響。方法將100例 AECOPD 患者按入院的先後順序分為研究組和對照組,每組50例。對照組給予抗生素、多索茶堿、阿託伐他汀鈣等常規基礎治療;觀察組在對照組常規治療基礎上加用信必可都保吸入。觀察治療前、治療14 d 後兩組患者血清白細胞介素(IL-13)、C 反應蛋白(CRP)錶達水平及肺功能的變化。結果治療前兩組患者血清 IL-13、CRP 錶達水平及肺功能比較差異無統計學意義(P >0.05)。治療14 d 後,觀察組患者血清 IL-13、CRP 錶達水平明顯降低(P <0.05),肺活量(FVC)、最大呼氣峰流速(PEF)、第1秒用力呼氣容積(FEV1)、第1秒用力呼氣容積佔用力肺活量之比(FEV1/FVC)變化明顯高于對照組(P <0.05),觀察組總有效率明顯高于對照組(P <0.05)。結論信必可都保聯閤阿託伐他汀鈣能明顯降低慢性阻塞性肺疾病急性加重期患者炎癥因子水平,顯著改善肺功能。
목적:관찰포지내덕복막특라흡입제(신필가도보)연합아탁벌타정개대만성조새성폐질병급성가중기(AECOPD)환자염증인자급폐공능적영향。방법장100례 AECOPD 환자안입원적선후순서분위연구조화대조조,매조50례。대조조급여항생소、다색다감、아탁벌타정개등상규기출치료;관찰조재대조조상규치료기출상가용신필가도보흡입。관찰치료전、치료14 d 후량조환자혈청백세포개소(IL-13)、C 반응단백(CRP)표체수평급폐공능적변화。결과치료전량조환자혈청 IL-13、CRP 표체수평급폐공능비교차이무통계학의의(P >0.05)。치료14 d 후,관찰조환자혈청 IL-13、CRP 표체수평명현강저(P <0.05),폐활량(FVC)、최대호기봉류속(PEF)、제1초용력호기용적(FEV1)、제1초용력호기용적점용력폐활량지비(FEV1/FVC)변화명현고우대조조(P <0.05),관찰조총유효솔명현고우대조조(P <0.05)。결론신필가도보연합아탁벌타정개능명현강저만성조새성폐질병급성가중기환자염증인자수평,현저개선폐공능。
Objective To observe the effect of Symbicort Turbuhaler combined with Atorvastatin calcium in inflammatory factors and lung function in the patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods 100 patients with AECOPD were randomly divided into the control group (50 cases),which were given the basis of conventional therapy and Atorvastatin calcium.The study group(50 cases),which were given Symbicort Turbuhaler on the basis of the control group.The two groups were observed the chang the serum IL-13,CRP and lung function after treatment for 14 days. Results There was no difference in inflammatory factors and lung function in the two groups before treatment (P >0.05).The expressions of CRP、IL-13 were decreased significantly in the study group than the control group after treatment for 14 days(P <0.05),FVC,PEF,FEV1,FEV1 /FVC were increased significantly(P <0.05), the clinical efficacy of the study group were better than control group(P <0.05 ). Conclusion Symbicort Turbuhaler combined with Atorvastatin calcium could significantly improve the lung function,decrease the level of inflammatory in the patients with acute exacerbation of chronic obstructive pulmonary disease.